Vietnam Interventional Cardiology Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Vietnam Interventional Cardiology Market Size

• The Vietnam interventional cardiology market size was valued at USD 58.49 million in 2024 and is expected to reach USD 99.01 million by 2032, at a CAGR of 6.80% during the forecast period
• The market growth is largely fueled by the growing adoption of advanced cardiovascular treatments and continuous technological progress in interventional cardiology devices, leading to enhanced diagnostic and therapeutic outcomes in both public and private healthcare facilities in Vietnam
• Furthermore, rising patient demand for minimally invasive and catheter-based procedures, alongside the government's increased healthcare spending and hospital infrastructure development, is establishing interventional cardiology solutions as the preferred choice for managing complex cardiovascular conditions. These converging factors are accelerating the uptake of interventional cardiology procedures, thereby significantly boosting the Vietnam Interventional Cardiology Market's growth

Vietnam Interventional Cardiology Market Analysis

• Interventional cardiology procedures are becoming increasingly essential in Vietnam’s healthcare system due to their minimally invasive nature, faster recovery times, and reduced hospitalization compared to traditional cardiac surgeries. These procedures, including angioplasty and stent placement, are gaining rapid traction in both public and private hospitals
• The market growth in Vietnam is largely driven by the rising prevalence of coronary artery disease, increasing aging population, growing awareness of cardiovascular health, and the adoption of advanced cardiac care technologies
• Vietnam accounted for the largest share in the Southeast Asia Interventional Cardiology Market with a revenue share of 36.4% in 2024, owing to the country’s expanding healthcare infrastructure, strategic investments in cardiology departments, and rising demand for catheter-based interventions
• Moreover, the Vietnamese government’s initiatives to upgrade provincial hospitals, along with public-private partnerships and collaborations with global device manufacturers, are significantly boosting access to modern interventional cardiology services
• The percutaneous coronary intervention (PCI) segment dominated the Vietnam interventional cardiology market with a market share of 33.8% in 2024, attributed to its status as the standard of care for coronary artery disease and its widespread adoption across tertiary hospitals and cardiac care centers

Report Scope and Vietnam Interventional Cardiology Market Segmentation         

Vietnam Interventional Cardiology Market Trends

“Advancements in Minimally Invasive Cardiac Interventions”

• A significant and accelerating trend in the Vietnam interventional cardiology market is the growing adoption of minimally invasive procedures for the diagnosis and treatment of cardiovascular diseases. These interventions, such as angioplasty and stent placements, are becoming increasingly preferred over traditional open-heart surgeries due to shorter recovery times, reduced hospital stays, and lower risk of complications
• For instance, Vietnam has seen a rise in the number of cardiac catheterization labs, enabling broader access to percutaneous coronary intervention (PCI) and coronary thrombectomy procedures. This expansion is supported by increased government investment in cardiovascular infrastructure and the integration of advanced imaging techniques
• The market is also witnessing significant growth due to the increasing prevalence of cardiovascular conditions, including ischemic heart disease and coronary artery disease, particularly in the aging population. The rising number of geriatric patients has increased the demand for less invasive solutions with better clinical outcomes
• Moreover, advancements in drug-eluting stents (DES), balloon angioplasty devices, and intravascular ultrasound (IVUS) systems are enhancing procedural success rates and long-term efficacy, further driving market penetration
• Companies operating in the market are focusing on launching next-generation guidewires, catheters, and fractional flow reserve (FFR) technologies to provide more accurate, safe, and effective interventions. Strategic collaborations between hospitals and medical device manufacturers are also improving procedural capabilities and clinical expertise across Vietnam
• The demand for interventional cardiology solutions is rapidly increasing across hospitals and cath labs, as the country continues to prioritize cardiovascular health through public health programs, skilled physician training, and access to modern cardiac care facilities

Vietnam Interventional Cardiology Market Dynamics

Driver

“Growing Need Due to Rising Cardiovascular Disease Burden and Technological Advancements”

• The increasing prevalence of cardiovascular diseases such as coronary artery disease, coupled with rising obesity, diabetes, and hypertension rates, is significantly driving demand for interventional cardiology procedures in Vietnam
• For instance, in 2024, the Ministry of Health in Vietnam reported a steady rise in ischemic heart disease, urging hospitals to adopt minimally invasive procedures such as angioplasty and stent placements as front-line treatments
• As awareness of early cardiac intervention grows among patients and healthcare providers, interventional cardiology offers the advantage of reduced hospital stay, faster recovery, and better long-term outcomes compared to open-heart surgery
• Furthermore, Vietnam’s rapidly modernizing healthcare system and the government’s push to upgrade provincial cardiac care facilities are making advanced catheter-based procedures more accessible to the broader population
• The introduction of drug-eluting stents, image-guided systems, and hybrid cardiac cath labs are transforming how hospitals approach heart care. In addition, private healthcare chains are investing in cardiovascular infrastructure to meet increasing urban demand

Restraint/Challenge

“Limited Access in Rural Areas and High Procedure Costs”

• A major challenge in the Vietnam interventional cardiology market is the uneven distribution of healthcare infrastructure, with advanced interventional cardiology services concentrated mainly in urban centers such as Hanoi and Ho Chi Minh City
• For instance, rural patients often face long travel times and financial burdens to access tertiary care hospitals with catheterization labs. This geographic disparity limits the broader adoption of life-saving cardiac procedures
• Another restraint is the relatively high cost of interventional devices and imported stents, which can pose a financial strain on middle- and low-income populations without comprehensive insurance coverage
• Despite government health insurance expansion, many procedures still require significant out-of-pocket payments, deterring early diagnosis and timely treatment
• Overcoming these challenges through expanded insurance schemes, investment in regional cardiac centers, and strategic partnerships with device manufacturers to lower procurement costs will be critical for long-term market sustainability

Vietnam Interventional Cardiology Market Scope

The market is segmented on the basis of product, type, indication, age, end user, and distribution channel.

• By Product

On the basis of product, the Vietnam interventional cardiology market is segmented into guidewire, catheters, coronary stents, angioplasty balloon, vascular closure device (VCD), intravascular ultrasound (IVUS), hemodynamic flow alteration devices, plaque modification devices, fractional flow reserve (FFR), and accessories. Coronary Stents held the largest revenue share of 28.4% in 2024, owing to widespread use in PCI procedures.

Angioplasty Balloons are projected to witness the fastest CAGR of 9.6% from 2025 to 2032, due to increasing adoption of drug-coated and cutting balloon technologies.

• By Type

On the basis of type, the Vietnam interventional cardiology market is segmented into conventional and advanced. Conventional devices accounted for 61.3% of the market share in 2024, driven by their accessibility and cost-effectiveness.

Advanced devices are expected to grow at a fastest CAGR of 8.9% from 2025 to 2032, due to rising preference for precision-based interventional technologies.

• By Indication

On the basis of indication, the Vietnam interventional cardiology market is segmented into cardiac catheterization, PCI, coronary thrombectomy, atherectomy, balloon angioplasty, stent implantation, hypothermia/intra-aortic balloon pump, patent foramen ovale closure, and others. Percutaneous coronary intervention (PCI) dominated the segment with a 33.8% revenue share in 2024, as it remains the standard care for coronary artery disease.

Coronary Thrombectomy is projected to grow at the fastest CAGR of 10.2% during the forecast period, due to its critical role in acute myocardial infarction cases.

• By Age

On the basis of age, the Vietnam interventional cardiology market is segmented into adults, paediatric, and geriatric. Adults accounted for 64.7% of the market share in 2024 due to the high incidence of lifestyle-related cardiovascular diseases.

The Geriatric segment is anticipated to grow at a fastest CAGR of 8.5% during the forecast period, owing to the aging population and increasing demand for cardiac interventions in elderly patients.

• By End User

On the basis of end user, the Vietnam interventional cardiology market is segmented into hospitals, cath laboratories, academic and research institutions, and others. Hospitals dominated with 54.2% market share in 2024 due to integrated cardiac care services and high procedure volumes.

Cath Laboratories are expected to expand at a fastest CAGR of 9.1% during the forecast period, driven by the rise in standalone and specialized interventional facilities.

• By Distribution Channel

On the basis of distribution channel, the Vietnam interventional cardiology market is segmented into direct tender, third party distributor, and retail sales. Direct Tender accounted for 46.3% market share in 2024 as most hospitals and government institutions procure bulk devices through tenders.

Third party distributor segment is projected to grow at a CAGR of 9.8% during the forecast period, due to increasing partnerships between manufacturers and regional distribution networks.

Vietnam Interventional Cardiology Market Regional Analysis

• Vietnam accounted for the largest share in the Southeast Asia interventional cardiology market with a revenue share of 36.4% in 2024, owing to the country’s expanding healthcare infrastructure, strategic investments in cardiology departments, and rising demand for catheter-based interventions
• Patients in the country are increasingly gaining access to advanced interventional procedures such as percutaneous coronary interventions (PCI), supported by the rising number of specialized cardiac centers and skilled healthcare professionals
• This market growth is further fueled by rising health insurance coverage, medical tourism in urban centers such as Ho Chi Minh City, and growing public-private partnerships to invest in modern catheterization labs

Vietnam Interventional Cardiology Market Share

The Vietnam interventional cardiology market industry is primarily led by well-established companies, including:

• Medtronic (Ireland)
• Teleflex Incorporated (U.S.)
• Abbott (U.S.)
• Boston Scientific Corporation (U.S.)
• B. Braun SE (Germany)
• USM HEALTHCARE (Singapore)
• BIOTRONIK (Germany)
• Stryker (U.S.)
• BD (U.S.)
• Medinol Ltd. (Israel)
• AngioDynamics (U.S.)

Latest Developments in Vietnam interventional cardiology market

• In February 2023, IS Medical AG launched OPN NC percutaneous transluminal coronary angioplasty (PTCA) dilatation catheter with Twin-Wall technology. The OPN NC device’s Twin-Wall design provides a high-pressure resistance with a rated burst pressure of 35 atm with low compliance
• In January 2023, The U.S. FDA approved the BioFreedom Drug Coated Coronary Stent (DCS) System P190020 from Biosensors International. The BioFreedom Drug Coated Coronary Stent System is intended to treat a narrowed blood vessel (coronary artery) caused by coronary artery disease
• In February 2025, Terumo Vietnam Medical Equipment and Daiichi Sankyo Vietnam signed an MOU to enhance interventional cardiology services in Vietnam through joint scientific symposia, hands-on PCI workshops, and continuous medical education aimed at improving acute coronary syndrome management nationwide

SKU-66598